Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 12/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.34 |
| ▸ | CDK4 | P11802 | 7/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873640 | 0.92 | IRAK1 (0.39) | IRAK1IRAK4SCN9ABRAFRAF1 | |
| SCHEMBL2870590 | 0.92 | IRAK1 (0.39) | IRAK1IRAK4SCN9ABRAFRAF1 | |
| SCHEMBL2870826 | 0.87 | BRAF (0.40) | IRAK1IRAK4SCN9ACCND1CDK4 | |
| SCHEMBL388891 | 0.83 | SCN9A (0.42) | IRAK1IRAK4SCN9ACCND1CDK6 | |
| SCHEMBL593958 | 0.82 | CCND1 (0.33) | CCND1CDK6CDK4 | |
| SCHEMBL392624 | 0.80 | SCN9A (0.41) | IRAK1IRAK4SCN9ACCND1CDK4 | |
| SCHEMBL387910 | 0.79 | SCN9A (0.38) | IRAK1IRAK4SCN9ACCND1CDK6 | |
| SCHEMBL391680 | 0.79 | SCN9A (0.38) | IRAK1IRAK4SCN9ACCND1CDK6 | |
| SCHEMBL391908 | 0.79 | SCN9A (0.41) | IRAK1IRAK4SCN9ACCND1CDK4 | |
| SCHEMBL388963 | 0.79 | BRAF (0.39) | IRAK1IRAK4SCN9ACCND1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101628-B2 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-8063212-B2 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2125794-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2125793-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-04-01 | — | — | US | disclosed |
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, BUB1B, BUB1 | IRAK1 3552/4885IRAK4 3836/4885SCN9A 4282/4885 |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, AURKC, BUB1B | IRAK1 3395/4885IRAK4 3665/4885SCN9A 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.